Matches in Nanopublications for { ?s ?p "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP189835.RAsDZ4W3WrYIQJMBCVLQTFR8Xo2Obqw0Xk9y73atFe7RM130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP189835.RAsDZ4W3WrYIQJMBCVLQTFR8Xo2Obqw0Xk9y73atFe7RM130_provenance.
- NP190287.RAtQ2vZQtwBnx4sngM8FqdbGlMrU-70oeePOnpKEeExGk130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP190287.RAtQ2vZQtwBnx4sngM8FqdbGlMrU-70oeePOnpKEeExGk130_provenance.
- assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP189944.RAx1S87BpFx-ybpb24r9-6J1yGrhhXGfo2vlFq_YUbu6Q130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP189944.RAx1S87BpFx-ybpb24r9-6J1yGrhhXGfo2vlFq_YUbu6Q130_provenance.
- NP190360.RALT7lwE7FD492pWvil6QyF20O8p_skCzDBS34TWppWQg130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP190360.RALT7lwE7FD492pWvil6QyF20O8p_skCzDBS34TWppWQg130_provenance.